

# Maria Gabriella Matera

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4843893/maria-gabriella-matera-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167  
papers

3,460  
citations

32  
h-index

50  
g-index

181  
ext. papers

4,305  
ext. citations

5.1  
avg, IF

6.12  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 167 | Beyond Dual Bronchodilation - Triple Therapy, When and Why.. <i>International Journal of COPD</i> , <b>2022</b> , 17, 165-180   | 3    | 2         |
| 166 | Can FeNO be a biomarker in the post-COVID-19 patients monitoring?. <i>Respiratory Medicine</i> , <b>2022</b> , 193, 106745  | 4.6  | 0         |
| 165 | Bronchodilators for Airway Disease <b>2022</b> , 712-728  |      | 0         |
| 164 | The future of inhalation therapy in chronic obstructive pulmonary disease.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2022</b> , 3, 100092  | 3    | 1         |
| 163 | Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. <i>Drugs</i> , <b>2021</b> , 1   | 12.1 | 1         |
| 162 | New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , <b>2021</b> , 13, 291-302   | 3    | 4         |
| 161 | Sex differences in COPD management. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 323-332   | 3.8  | 3         |
| 160 | Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. <i>Vaccines</i> , <b>2021</b> , 9,   | 5.3  | 17        |
| 159 | Comments on "Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations" by DSAmato. <i>Multidisciplinary Respiratory Medicine</i> , <b>2021</b> , 16, 757 | 3    | 2         |
| 158 | Classes of drugs that target the cellular components of inflammation under clinical development for COPD. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 1015-1027                   | 3.8  | 3         |
| 157 | Management of COPD patients during COVID: difficulties and experiences. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1025-1033  | 3.8  | 0         |
| 156 | Step-up and step-down approaches in the treatment of asthma. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1159-1168   | 3.8  | 2         |
| 155 | Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation. <i>Respiratory Medicine</i> , <b>2021</b> , 182, 106401   | 4.6  | 5         |
| 154 | Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients. <i>Archivos De Bronconeumologia</i> , <b>2021</b> ,              | 0.7  |           |
| 153 | Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 1-9        | 3.8  | 0         |
| 152 | Guidance on nebulization during the current COVID-19 pandemic. <i>Respiratory Medicine</i> , <b>2021</b> , 176, 1062366   | 4.6  | 19        |
| 151 | Prospects for severe asthma treatment. <i>Current Opinion in Pharmacology</i> , <b>2021</b> , 56, 52-60   | 5.1  | 6         |

|     |   |      |    |
|-----|---|------|----|
| 150 | Prospects for COPD treatment. <i>Current Opinion in Pharmacology</i> , <b>2021</b> , 56, 74-84  | 5.1  | 18 |
| 149 | Drug interaction and chronic obstructive respiratory disorders.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2021</b> , 2, 100009   | 3    | 2  |
| 148 | Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , <b>2021</b> , 18, 891-906   | 8    | 4  |
| 147 | Long-acting muscarinic antagonists and small airways in asthma: Which link?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 1990-2001                                | 9.3  | 7  |
| 146 | Treatable Mechanisms in Asthma. <i>Molecular Diagnosis and Therapy</i> , <b>2021</b> , 25, 111-121  | 4.5  | 5  |
| 145 | Current long-acting muscarinic antagonists for the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2343-2357  | 4    | 0  |
| 144 | Use of Thiols in the Treatment of COVID-19: Current Evidence. <i>Lung</i> , <b>2021</b> , 199, 335-343  | 2.9  | 2  |
| 143 | Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1415-1425                                | 3.8  | 1  |
| 142 | Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients. <i>Respiratory Medicine</i> , <b>2021</b> , 184, 106470                | 4.6  | 5  |
| 141 | An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. <i>Biologics: Targets and Therapy</i> , <b>2021</b> , 15, 363-374                              | 4.4  | 2  |
| 140 | Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. <i>Pharmacological Research</i> , <b>2021</b> , 172, 105801                | 10.2 | 3  |
| 139 | Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , <b>2021</b> , 187, 106569  | 4.6  | 7  |
| 138 | Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 723-738 | 5.9  | 1  |
| 137 | Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. <i>Expert Review of Respiratory Medicine</i> , <b>2020</b> , 14, 621-635                                      | 3.8  | 1  |
| 136 | Implications of the Adiponectin System in Non-Small Cell Lung Cancer Patients: A Case-Control Study. <i>Biomolecules</i> , <b>2020</b> , 10,  | 5.9  | 7  |
| 135 | The role of triple therapy in the management of COPD. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 865-874   | 3.8  | 4  |
| 134 | TSLP Inhibitors for Asthma: Current Status and Future Prospects. <i>Drugs</i> , <b>2020</b> , 80, 449-458   | 12.1 | 26 |
| 133 | A review of the pharmacokinetics of M muscarinic receptor antagonists used for the treatment of asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 143-148                   | 5.5  | 9  |

|     |  |      |    |
|-----|--|------|----|
| 132 | Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2020</b> , 17, 215-223 | 2    | 0  |
| 131 | Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?. <i>Respiratory Medicine</i> , <b>2020</b> , 168, 105996  | 4.6  | 91 |
| 130 | Emerging muscarinic receptor antagonists for the treatment of asthma. <i>Expert Opinion on Emerging Drugs</i> , <b>2020</b> , 25, 123-130  | 3.7  | 5  |
| 129 | Antitrypsin deficiency and chronic respiratory disorders. <i>European Respiratory Review</i> , <b>2020</b> , 29,   | 9.8  | 22 |
| 128 | Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 1150-1163                                  | 8.6  | 24 |
| 127 | Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , <b>2020</b> , 6, 47-66   | 3    | 26 |
| 126 | A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2020</b> , 60, 101883   | 3.5  | 1  |
| 125 | Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. <i>Drugs</i> , <b>2020</b> , 80, 1799-1809   | 12.1 | 8  |
| 124 | The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,   | 5.1  | 2  |
| 123 | Pharmacological management of adult patients with acute respiratory distress syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2169-2183  | 4    | 3  |
| 122 | Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 4750-4765  | 8.6  | 8  |
| 121 | Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2020</b> , 13, 261-271   | 2.1  | 2  |
| 120 | Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. <i>Respiratory Medicine</i> , <b>2020</b> , 171, 106114   | 4.6  | 14 |
| 119 | Advances with glucocorticoids in the treatment of asthma: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2305-2316   | 4    | 9  |
| 118 | New perspectives on the role of muscarinic antagonists in asthma therapy. <i>Expert Review of Respiratory Medicine</i> , <b>2020</b> , 14, 817-824   | 3.8  | 4  |
| 117 | Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. <i>Monaldi Archives for Chest Disease</i> , <b>2020</b> , 90,        | 2.7  | 2  |
| 116 | Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. <i>Advances in Therapy</i> , <b>2019</b> , 36, 3291-3298  | 4.1  | 6  |
| 115 | Ultra-LABAs for the treatment of asthma. <i>Respiratory Medicine</i> , <b>2019</b> , 156, 47-52  | 4.6  | 6  |

|     |   |      |    |
|-----|---|------|----|
| 114 | A potential role of triple therapy for asthma patients. <i>Expert Review of Respiratory Medicine</i> , <b>2019</b> , 13, 1079-1085  | 3.8  | 13 |
| 113 | Enfentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 827-833  | 5.9  | 18 |
| 112 | Isolated airways in equine respiratory pharmacology: They never lie. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 59, 101849  | 3.5  | 2  |
| 111 | Monoclonal antibodies in severe asthma: is it worth it?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 517-520  | 5.5  | 5  |
| 110 | Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , <b>2019</b> , 154, 86-92  | 4.6  | 13 |
| 109 | Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. <i>Trends in Pharmacological Sciences</i> , <b>2019</b> , 40, 452-463   | 13.2 | 22 |
| 108 | Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , <b>2019</b> , 20, 104                            | 7.3  | 30 |
| 107 | Response. <i>Chest</i> , <b>2019</b> , 155, 1079-1080   | 5.3  | 1  |
| 106 | Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. <i>Respiratory Medicine</i> , <b>2019</b> , 153, 3-13  | 4.6  | 19 |
| 105 | Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 56, 39-50  | 3.5  | 10 |
| 104 | Bronchodilators in subjects with asthma-related comorbidities. <i>Respiratory Medicine</i> , <b>2019</b> , 151, 43-48   | 4.6  | 7  |
| 103 | Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. <i>Chest</i> , <b>2019</b> , 155, 758-770   | 5.3  | 56 |
| 102 | Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. <i>Multidisciplinary Respiratory Medicine</i> , <b>2019</b> , 14, 25  | 3    | 6  |
| 101 | Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 58, 101828  | 3.5  | 8  |
| 100 | Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 59, 101841 | 3.5  | 20 |
| 99  | Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting $\beta$ Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. <i>Pulmonary Therapy</i> , <b>2019</b> , 5, 117-126  | 3    | 6  |
| 98  | Pharmacological treatment and current controversies in COPD. <i>F1000Research</i> , <b>2019</b> , 8,  | 3.6  | 19 |
| 97  | Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 737-750  | 4    | 12 |

|    |  |     |    |
|----|--|-----|----|
| 96 | The future of bronchodilation: looking for new classes of bronchodilators. <i>European Respiratory Review</i> , <b>2019</b> , 28,  | 9.8 | 14 |
| 95 | Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 49, 88-94  | 3.5 | 6  |
| 94 | A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 509-517  | 4.1 | 4  |
| 93 | Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 50, 28-37                           | 3.5 | 8  |
| 92 | Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 40, 95-103   | 5.1 | 38 |
| 91 | Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 239-245   | 5.5 | 8  |
| 90 | Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 49, 20-26 | 3.5 | 2  |
| 89 | Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. <i>Respiratory Research</i> , <b>2018</b> , 19, 65                                       | 7.3 | 20 |
| 88 | Efficacy and safety profile of xanthines in COPD: a network meta-analysis. <i>European Respiratory Review</i> , <b>2018</b> , 27,  | 9.8 | 32 |
| 87 | The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 589-596  | 4.1 | 8  |
| 86 | Impact of doxofylline in COPD: A pairwise meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 51, 1-9  | 3.5 | 14 |
| 85 | How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 435-446   | 5.5 | 13 |
| 84 | An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 43-54                         | 3.8 | 8  |
| 83 | N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. <i>Biomedicine and Pharmacotherapy</i> , <b>2018</b> , 103, 1-8                                | 7.5 | 11 |
| 82 | Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 1093-1094                    | 5.4 |    |
| 81 | Impact of erdoesteine on chronic bronchitis and COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 185-194  | 3.5 | 13 |
| 80 | Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 1101-1111      | 5.5 | 7  |
| 79 | Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 2043-2053                          | 4   | 3  |

|    |  |      |    |
|----|--|------|----|
| 78 | Triple therapy single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , <b>2018</b> , 52,                            | 13.6 | 78 |
| 77 | β-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 40, 142-146   | 5.1  | 15 |
| 76 | Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. <i>European Journal of Pharmacology</i> , <b>2018</b> , 832, 114-119 | 5.3  | 9  |
| 75 | Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 693-708                                      | 3.8  | 16 |
| 74 | LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , <b>2017</b> , 26,  | 9.8  | 43 |
| 73 | Role of muscarinic antagonists in asthma therapy. <i>Expert Review of Respiratory Medicine</i> , <b>2017</b> , 11, 239-253   | 3.3  | 20 |
| 72 | Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. <i>Respiratory Research</i> , <b>2017</b> , 18, 26    | 7.3  | 37 |
| 71 | Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , <b>2017</b> , 124, 6-14   | 4.6  | 97 |
| 70 | The Challenges of Precision Medicine in COPD. <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 345-355   | 4.5  | 28 |
| 69 | An update on the pharmacotherapeutic management of lower respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 973-988  | 4    | 6  |
| 68 | Adherence to COPD treatment: Myth and reality. <i>Respiratory Medicine</i> , <b>2017</b> , 129, 117-123  | 4.6  | 37 |
| 67 | Bronchodilator therapy for chronic cough. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 47, 88-92   | 3.5  | 8  |
| 66 | Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 148-158   | 3.5  | 45 |
| 65 | Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. <i>Drugs</i> , <b>2017</b> , 77, 721-732   | 12.1 | 20 |
| 64 | Pharmacogenetic and pharmacogenomic considerations of asthma treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 1159-1167  | 5.5  | 4  |
| 63 | Fixed-Dose Combination Inhalers. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 237, 117-129   | 3.2  | 12 |
| 62 | Muscarinic Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 237, 41-62   | 3.2  | 15 |
| 61 | Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. <i>European Journal of Pharmacology</i> , <b>2017</b> , 812, 147-154                       | 5.3  | 17 |

|    |  |     |    |
|----|--|-----|----|
| 60 | Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 1007-1013   | 5.5 | 23 |
| 59 | Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 526-532                             | 2   | 16 |
| 58 | Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 552-563   | 2   | 61 |
| 57 | Tiotropium formulations and safety: a network meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , <b>2017</b> , 8, 17-30   | 3.5 | 20 |
| 56 | Assessing the viability of long-acting $\beta_2$ agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 129-136  | 5.5 | 4  |
| 55 | The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. <i>International Journal of COPD</i> , <b>2017</b> , 12, 3469-3485  | 3   | 27 |
| 54 | Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 791-3   | 5.4 | 6  |
| 53 | Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2016</b> , 55, 804-814   | 5.7 | 28 |
| 52 | Brain natriuretic peptide: Much more than a biomarker. <i>International Journal of Cardiology</i> , <b>2016</b> , 221, 1031-8  | 3.2 | 42 |
| 51 | Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1133-46   | 4.1 | 39 |
| 50 | Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 813-22   | 5.5 | 5  |
| 49 | Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. <i>Respiratory Medicine</i> , <b>2016</b> , 117, 150-3  | 4.6 | 20 |
| 48 | Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 36, 1-9  | 3.5 | 35 |
| 47 | Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 771-7 | 3.8 |    |
| 46 | Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 977-88   | 4   | 8  |
| 45 | Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , <b>2016</b> , 11, 73-9   | 3   | 2  |
| 44 | Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , <b>2016</b> , 17, 70                                | 7.3 | 58 |
| 43 | The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. <i>Respiratory Medicine</i> , <b>2016</b> , 117, 190-7   | 4.6 | 95 |



|    |   |      |     |
|----|---|------|-----|
| 42 | Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 40, 15-21  | 3.5  | 25  |
| 41 | Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. <i>Drug Safety</i> , <b>2016</b> , 39, 501-8   | 5.1  | 26  |
| 40 | A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. <i>Chest</i> , <b>2016</b> , 149, 1181-96   | 5.3  | 160 |
| 39 | The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , <b>2016</b> , 11, 733-44   | 6.2  | 26  |
| 38 | Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 40, 95-103   | 3.5  | 80  |
| 37 | Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , <b>2016</b> , 76, 1257-1270  | 12.1 | 26  |
| 36 | Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. <i>European Journal of Pharmacology</i> , <b>2015</b> , 761, 168-73   | 5.3  | 79  |
| 35 | Cardiovascular disease in patients with COPD. <i>Lancet Respiratory Medicine</i> , <b>2015</b> , 3, 593-5   | 35.1 | 16  |
| 34 | Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1019-25  | 4.6  | 16  |
| 33 | QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1079-90  | 4    | 13  |
| 32 | Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 31, 51-4  | 3.5  | 8   |
| 31 | Effects of chronic treatment with the new ultra-long-acting $\beta_2$ -adrenoceptor agonist indacaterol alone or in combination with the $\beta_1$ -adrenoceptor blocker metoprolol on cardiac remodelling. <i>British Journal of Pharmacology</i> , <b>2015</b> , 172, 3627-37 | 8.6  | 22  |
| 30 | Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. <i>Drugs</i> , <b>2015</b> , 75, 1575-85  | 12.1 | 22  |
| 29 | Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. <i>Life Sciences</i> , <b>2015</b> , 131, 44-50  | 6.8  | 17  |
| 28 | Novel glucocorticoid receptor agonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1473-82   | 5.9  | 14  |
| 27 | Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , <b>2015</b> , 24, 451-61   | 9.8  | 112 |
| 26 | Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1305-11   | 4.6  | 44  |
| 25 | Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia. <i>European Journal of Pharmacology</i> , <b>2015</b> , 765, 463-71  | 5.3  | 21  |

|    |  |      |    |
|----|--|------|----|
| 24 | Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. <i>European Journal of Pharmacology</i> , <b>2015</b> , 761, 383-90                                      | 5.3  | 28 |
| 23 | Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. <i>Therapeutics and Clinical Risk Management</i> , <b>2015</b> , 11, 1805-11  | 2.9  | 6  |
| 22 | Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 32, 15-23 | 3.5  | 37 |
| 21 | Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 533-41  | 4.1  | 29 |
| 20 | Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 35-41   | 3.8  | 8  |
| 19 | Indacaterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 107-15  | 4    | 6  |
| 18 | Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 31, 15-27   | 3.5  | 47 |
| 17 | Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2015</b> , 12, 175-81   | 2    | 59 |
| 16 | Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2015</b> , 9, 5-12  | 3.8  | 4  |
| 15 | Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?. <i>Drugs</i> , <b>2014</b> , 74, 1983-92   | 12.1 | 23 |
| 14 | PDE inhibitors currently in early clinical trials for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , <b>2014</b> , 23, 1267-75  | 5.9  | 27 |
| 13 | N-acetylcysteine in COPD may be beneficial, but for whom?. <i>Lancet Respiratory Medicine</i> , <b>2014</b> , 2, 166-7   | 35.1 | 12 |
| 12 | Bronchodilators: current and future. <i>Clinics in Chest Medicine</i> , <b>2014</b> , 35, 191-201  | 5.3  | 54 |
| 11 | Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. <i>European Journal of Pharmacology</i> , <b>2014</b> , 745, 135-43  | 5.3  | 71 |
| 10 | Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2013</b> , 26, 307-17  | 3.5  | 49 |
| 9  | Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2013</b> , 346, 414-23  | 4.7  | 67 |
| 8  | The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2013</b> , 26, 325-31  | 3.5  | 32 |
| 7  | Emerging drugs for chronic obstructive pulmonary disease. <i>Expert Opinion on Emerging Drugs</i> , <b>2012</b> , 17, 61-82  | 3.7  | 20 |

|   |  |      |    |
|---|--|------|----|
| 6 | Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. <i>Trends in Pharmacological Sciences</i> , <b>2011</b> , 32, 495-506  | 13.2 | 74 |
| 5 | Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2011</b> , 45, 704-10                       | 5.7  | 32 |
| 4 | Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2010</b> , 23, 1-8 | 3.5  | 36 |
| 3 | TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2010</b> , 23, 121-8  | 3.5  | 91 |
| 2 | Long- And Ultra-Long-Acting $\beta_2$ -Agonists81-101  |      |    |
| 1 | An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. <i>Expert Opinion on Pharmacotherapy</i> ,1-12  | 4    | 1  |